AURA News and Press, Aura Biosciences Inc. From 09/27/22

Company to Host Virtual Investor Day with Ocular Oncology Experts on Monday, October 3, 2022, at 11:30 a.m. Eastern Time Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for mu...

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Phase 2 data evaluating the safety of suprachoroidal administration using its first ...

On Track to Initiate Pivotal Trial in Early-Stage Choroidal Melanoma in Q4 2022 On Track to Submit IND in Choroidal Metastasis in 2H 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugat...

Gainers: Curis ( CRIS ) +36% . Allarity Therapeutics ( ALLR ) +23% . Codiak BioSciences ( CDAK ) +21% . Cassava Sciences ( SAVA ) +17% .  AlerisLife ( ALR ) +11% . Losers: Blue Water Vaccines ( BWV ) -27% ...

Aura Biosciences press release ( NASDAQ: AURA ): Q2 GAAP EPS of -$0.46 beats by $0.01 . As of June 30, 2022, Aura had cash and cash equivalents and marketable securities totaling $122.1 million. Aura believes its current cash and cash equivalents and marketable securit...

On Track to Dose the First Patient in the Phase 1 Study Evaluating Belzupacap Sarotalocan (AU‑011) for the Treatment of Non-Muscle Invasive Bladder Cancer in Q3 2022 On Track to Initiate Pivotal Trial in Early-Stage Choroidal Melanoma in Q4 2022 Aura Bioscienc...

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, and Julie Feder, Chief Financi...

Aura Biosciences ( NASDAQ: AURA ) is trading higher in the morning hours Tuesday after JMP Securities issued an Outperform rating as it started coverage on the clinical-stage biotech citing its novel therapeutic platform. The virus-like drug conjugates (VDC) platform Aura ...

The U.S. Food and Drug Administration granted fast track designation to Aura Biosciences' ( NASDAQ: AURA ) belzupacap sarotalocan (AU-011) to treat non-muscle invasive bladder cancer. The company said AU-011 is its first virus-like drug conjugate product candidate...

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...